- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00888134
Selumetinib in Cancers With BRAF Mutations
Phase II Clinical Trial of the MEK 1/2 Inhibitor AZD6244 in Cancers With BRAF Mutations Identified by Prospective Genotypic Analysis
Study Overview
Detailed Description
PRIMARY OBJECTIVES:
I. To evaluate the objective response rate to AZD6244 (selumetinib) in patients with cancers other than melanoma in which BRAF mutations have been identified prospectively.
SECONDARY OBJECTIVES:
I. To evaluate progression-free survival in subjects treated with AZD6244. II. To obtain a preliminary estimate of the objective response rate in non-small cell lung cancers and colon cancers with BRAF mutations.
III. To explore biologic correlates of responsiveness to AZD6244, and specifically to correlate AKT pathway activity with sensitivity to MEK inhibition in the BRAF mutant class of tumors.
IV. To estimate the sensitivity and specificity of detection of the BRAF V600E mutation in circulating tumor cells (CTC) using a microfluidic platform (the 'CTC-chip').
OUTLINE:
Patients receive selumetinib orally (PO) twice daily (BID) for 3 weeks. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up every 3 months for 1 year, every 6 months for 1 year, and then annually thereafter.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02215
- Beth Israel Deaconess Medical Center
-
Boston, Massachusetts, United States, 02115
- Dana-Farber Cancer Institute
-
Boston, Massachusetts, United States, 02114
- Massachusetts General Hospital Cancer Center
-
Charlestown, Massachusetts, United States, 02129
- Massachusetts General Hospital
-
-
New York
-
New York, New York, United States, 10065
- Memorial Sloan-Kettering Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Ability to understand and willingness to sign a written informed consent document
- Histologically confirmed metastatic or unresectable solid tumor
- Results from tumor tissue analysis that show a glutamic acid-for-valine substitution at amino acid position 600 in the BRAF gene (V600E) or other activating BRAF mutation, as determined by high-throughput genotyping
- Patients may have received any number of prior systemic treatments for their cancer
- At least one measurable site of disease by CT, according to standard RECIST criteria 1.0
- ECOG performance status 0-1
- Absolute neutrophil count > 1500 per cubic mm
- Platelet count > 100,000 per cubic mm
- Hemoglobin > 9 g/dl
- Serum bilirubin < 1.5 x upper limit of normal
- Serum AST and ALT < 2.5 x upper limit of normal (=< 5 x upper limit of normal, for liver metastases)
- Serum creatinine < 1.5 x upper limit of normal
- For women of childbearing potential, negative serum pregnancy test and use of physician-approved method of birth control throughout the study
Exclusion Criteria:
- Estimated life expectancy > 12 weeks
- Patients with melanoma
- Have received chemotherapy or radiotherapy within 4 weeks prior to entering the study (6 weeks for nitrosoureas or mitomycin C), or a targeted therapy within 2 weeks prior to entering the study
- Have not recovered from adverse events due to agents previously administered (CTCAE v3 grade 1 or baseline)
- Currently receiving other investigational agents
- Known brain metastases, unless treated and stable off of corticosteroids for at least four weeks
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to AZD6244
- Prior treatment with a selective inhibitor of RAF or MEK (e.g., RAF265); (note: prior sorafenib is allowed)
Uncontrolled intercurrent illness, including but not limited to:
- Clinically significant active infection
- Symptomatic congestive heart failure, unstable angina pectoris, and/or cardiac arrhythmia other than atrial fibrillation
- Psychiatric illness/social situations that would limit compliance with study requirements
- Refractory nausea or vomiting, swallowing disorder, or malabsorption syndrome that would interfere with swallowing or absorbing the study medication
- Pregnant and/or breast-feeding women
Previous or concurrent malignancy, except for the following circumstances:
- Disease-free for at least three years and deemed by investigator to be at low risk for recurrence of that malignancy
- Individuals with the following cancers are eligible if diagnosed and treated within the past 5 years: cervical cancer in situ, and basal cell or squamous cell carcinoma of the skin)
- History of solid organ transplantation or other condition requiring the use of immunosuppressive medications
- Uncontrolled hypertension (systolic BP >= 150 or diastolic BP >= 100 that cannot be controlled with medications)
- A mean left ventricular ejection fraction (LVEF) less than 45%
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment (selumetinib)
Patients receive selumetinib PO BID for 3 weeks.
Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
|
Given PO
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective Response Rate in Patients With Cancers Other Than Melanoma
Time Frame: 4 years
|
Percentage of participants achieving either complete response (disappearance of all target lesions) or partial response (at least a 30% decrease in the sum of the longest diameter of target lesions, when compared with baseline) using CT (computed tomography) scans (which are done every 6 weeks).
|
4 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
AKT Pathway Activity
Time Frame: Up to 4 years
|
Correlation between response to AZD6244 and mutational analysis of AKT pathway (an intracellular signaling pathway important in regulating the cell cycle)
|
Up to 4 years
|
Objective Response Rate in Patients With Non-small Cell Lung Cancers and Colon Cancers
Time Frame: Up to 4 years
|
Percentage of participants with either colon cancer or non-small cell lung cancer achieving either complete response (disappearance of all target lesions) or partial response (at least a 30% decrease in the sum of the longest diameter of target lesions, when compared with baseline) using CT (computed tomography) scans.
|
Up to 4 years
|
Progression-free Survival
Time Frame: 4 months
|
Reported as percentage of participants alive and progression free at 4-months.
Will be estimated using Kaplan-Meier survival curves.
Confidence intervals will be calculated and reported.
|
4 months
|
Sensitivity and Specificity of Detection of the BRAF V600E Mutation in CTC Using the CTC-chip
Time Frame: Up to 4 years
|
Up to 4 years
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Donald Lawrence, Massachusetts General Hospital
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- NCI-2013-00576 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
- U01CA062490 (U.S. NIH Grant/Contract)
- P30CA006516 (U.S. NIH Grant/Contract)
- N01CM62206 (U.S. NIH Grant/Contract)
- 09-005 (Other Identifier: Massachusetts General Hospital Cancer Center)
- CDR642346
- 8281 (Other Identifier: CTEP)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Adult Solid Neoplasm
-
National Cancer Institute (NCI)Active, not recruitingAdult Solid NeoplasmUnited States
-
National Cancer Institute (NCI)Active, not recruitingAdult Solid NeoplasmUnited States
-
National Cancer Institute (NCI)Active, not recruitingErlotinib Hydrochloride and Irinotecan Hydrochloride in Treating Patients With Advanced Solid TumorsAdult Solid NeoplasmUnited States
-
National Cancer Institute (NCI)CompletedAdult Solid NeoplasmUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedAdult Solid NeoplasmUnited States
-
National Cancer Institute (NCI)CompletedAdult Solid NeoplasmUnited States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)TerminatedAdult Solid NeoplasmUnited States
-
National Cancer Institute (NCI)CompletedAdult Solid NeoplasmUnited States
-
National Cancer Institute (NCI)CompletedAdult Solid NeoplasmUnited States
-
National Cancer Institute (NCI)CompletedAdult Solid NeoplasmUnited States
Clinical Trials on Selumetinib
-
AstraZenecaCompleted
-
Shaheer A. KhanAstraZeneca; Melanoma Research AllianceCompleted
-
AstraZenecaCompleted
-
AstraZenecaCompletedHealthy Volunteers Bioavailability StudyUnited Kingdom
-
National Cancer Institute (NCI)Active, not recruitingNeurofibromatosis 1 (NF1) | Plexiform Neurofibromas (PN)United States
-
AstraZenecaApproved for marketingNF type1 With Inoperable Plexiform NeurofibromasUnited States
-
AstraZenecaCompleted
-
AstraZenecaMerck Sharp & Dohme LLCActive, not recruitingNeurofibromatosis Type 1United States, Spain, Germany, Netherlands, Russian Federation, Italy, Japan
-
AstraZenecaWithdrawnNeurofibromatosis Type 1 | Plexiform Neurofibromas | Post-operativeChina
-
The Christie NHS Foundation TrustAstraZeneca; University of ManchesterCompleted